Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy [0.03%]
SERENA-6试验：Camizestrant联合CDK4/6抑制剂治疗一线内分泌治疗中出现新兴ESR1突变的晚期乳腺癌患者的患者报告结局
E L Mayer,F-C Bidard,Y H Park et al.
E L Mayer et al.
Background: In SERENA-6, switching from aromatase inhibitor (AI) to camizestrant with continuation of CDK4/6 inhibitor (CDK4/6i) guided by emergence of ESR1m during first-line AI-CDK4/6i in patients with HR+ advanced brea...
Improved survival and rising incidence: insights from the largest retrospective study on leptomeningeal metastases in patients with NSCLC [0.03%]
生存改善和发病率上升：来自NSCLC患者脑膜转移最大规模回顾性研究的见解
J W J Huijs,E Le Rhun,L E L Hendriks
J W J Huijs
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study [0.03%]
来自NSCLC的脑膜转移的演变：一项国际性、多中心队列研究
M M Zheng,Y Xia,K Pan et al.
M M Zheng et al.
Background: Leptomeningeal metastatic disease (LMD) represents a devastating complication of non-small-cell lung cancer (NSCLC) with a poor prognosis. Our understanding of LMD is limited in the era of molecular testing an...
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study [0.03%]
Capivasertib联合阿比特龙治疗PTEN缺陷型转移性激素敏感性前列腺癌：CAPItello-281三期临床研究
Karim Fizazi,Noel W Clarke,Maria De Santis et al.
Karim Fizazi et al.
Background: In metastatic hormone-sensitive prostate cancer (mHSPC), PTEN deficiency results in PI3K/AKT pathway activation, providing an independent proliferative drive, which cannot be suppressed by androgen receptor pa...
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 [0.03%]
用于新诊断的晚期卵巢癌的鲁卡帕尼维持疗法：来自III期ATHENA-MONO/GOG-3020/ENGOT-ov45研究的五年随访的总生存率、无进展生存率和安全性 interim results
R S Kristeleit,S Ghamande,A Lisyanskaya et al.
R S Kristeleit et al.
Background: We report long-term efficacy and safety from the multicenter, randomized, double-blind, placebo-controlled, phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 (NCT03522246) study of first-line rucaparib maintenance for...
Novel pembrolizumab-based treatments as first-line therapy in advanced clear cell renal cell carcinoma: Substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial [0.03%]
新型帕博利珠单抗为基础的一线治疗晚期透明细胞肾癌方法：开放标签平台一期/二期KEYMAKER-U03试验的子研究03A
C Suarez,C Rojas,S J Shin et al.
C Suarez et al.
Background: First-line triplet therapy may expand clinical benefit for advanced clear cell renal cell carcinoma (ccRCC). The phase Ib/II KEYMAKER-U03 Substudy 03A (NCT04626479) investigated novel pembrolizumab (pembro)-ba...
A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo) [0.03%]
仑伐替尼联合依维莫司对比卡博替尼治疗PD-1免疫检查点抑制剂治疗后进展的转移性透明细胞肾癌患者：一项多中心、随机II期临床试验(LenCabo试验)
A W Hahn,J Chahoud,W P Skelton et al.
A W Hahn et al.
Background: First-line treatments for metastatic clear cell renal cell carcinoma (ccRCC) combine PD-1 immune checkpoint inhibition (ICI) with CTLA-4 ICI or angiogenesis targeted therapy (TT). Upon progression, common opti...
Antibody-Drug Conjugates in Combination Therapy: Defining the Next Chapter [0.03%]
抗体药物偶联物联合治疗：定义下一章节
Lillian L Siu,Thomas Powles
Lillian L Siu
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO [0.03%]
GONO的PARERE研究：RAS和BRAF野生型循环肿瘤DNA的化疗难治性转移性结直肠癌患者中帕尼单抗后使用瑞戈非尼与顺序相反时的有效性和安全性比较研究
P Ciracì,M M Germani,F Pietrantonio et al.
P Ciracì et al.
Background: Re-treatment with anti-EGFR monoclonal antibodies offers a promising approach to extend the continuum of care of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) with no mutations ...